Myriad Genetics (MYGN) to Release Quarterly Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN) is expected to announce its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $202.4680 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Monday, February 23rd. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.06. The firm had revenue of $209.80 million for the quarter, compared to analyst estimates of $207.57 million. Myriad Genetics had a negative net margin of 44.38% and a negative return on equity of 6.35%. The company’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter last year, the business posted $0.03 earnings per share. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Myriad Genetics Price Performance

Shares of NASDAQ:MYGN opened at $4.80 on Monday. The firm has a market cap of $453.33 million, a PE ratio of -1.22 and a beta of 1.81. The firm’s fifty day moving average is $4.77 and its 200-day moving average is $5.92. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.26 and a current ratio of 2.49. Myriad Genetics has a 52 week low of $3.76 and a 52 week high of $8.59.

Insider Buying and Selling at Myriad Genetics

In other news, CEO Samraat S. Raha bought 40,000 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average price of $5.00 per share, for a total transaction of $200,000.00. Following the completion of the acquisition, the chief executive officer directly owned 493,104 shares in the company, valued at approximately $2,465,520. This represents a 8.83% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director S. Louise Phanstiel bought 50,407 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was purchased at an average price of $4.80 per share, for a total transaction of $241,953.60. Following the acquisition, the director owned 233,951 shares of the company’s stock, valued at $1,122,964.80. This trade represents a 27.46% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 144,507 shares of company stock worth $694,548. 2.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Myriad Genetics

Several hedge funds and other institutional investors have recently bought and sold shares of MYGN. Millennium Management LLC lifted its holdings in Myriad Genetics by 41.1% in the fourth quarter. Millennium Management LLC now owns 6,700,158 shares of the company’s stock valued at $41,206,000 after buying an additional 1,951,831 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in Myriad Genetics by 157.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,442,912 shares of the company’s stock valued at $17,662,000 after buying an additional 1,492,405 shares during the period. Kent Lake PR LLC acquired a new position in Myriad Genetics in the second quarter valued at $6,638,000. Federated Hermes Inc. lifted its holdings in Myriad Genetics by 103,916.0% in the second quarter. Federated Hermes Inc. now owns 1,122,333 shares of the company’s stock valued at $5,960,000 after buying an additional 1,121,254 shares during the period. Finally, State Street Corp increased its stake in Myriad Genetics by 19.9% in the fourth quarter. State Street Corp now owns 5,966,567 shares of the company’s stock valued at $36,694,000 after purchasing an additional 990,075 shares in the last quarter. Institutional investors and hedge funds own 99.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Wells Fargo & Company cut their price target on shares of Myriad Genetics from $6.50 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Zacks Research upgraded shares of Myriad Genetics from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. UBS Group cut their price target on shares of Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Myriad Genetics in a report on Friday, March 27th. Finally, TD Cowen upgraded shares of Myriad Genetics to a “hold” rating in a report on Monday, April 13th. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.94.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.